Trial · NCT05431283
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | joint response and steroid free joint response | week 8 | evaluate the rate of patients achieving joint response and steroid free joint response on Ulcerative Colitis-associated spondyloarthropathy at week 8, 24, and 52 |
| Primary | joint response and steroid free joint response | week 24 | evaluate the rate of patients achieving joint response on Ulcerative Colitis-associated spondyloarthropathy |
| Primary | joint response and steroid free joint response | week 52 | evaluate the rate of patients achieving joint response and steroid free joint response on Ulcerative Colitis-associated spondyloarthropathy |
| Secondary | clinical intestinal response CIR | week 8 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | clinical intestinal response CIR | week 24 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | clinical intestinal response CIR | week 52 | To assess the rate of patients achieving a clinical intestinal response CIR for Ulcerative Colitis |
| Secondary | steroid free clinical intestinal remission | week 52 | To assess the rate of patients achieving a steroid free clinical intestinal remission for Ulcerative Colitis |
| Secondary | impact of Ulcerative Colitis | week 8 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
| Secondary | impact of Ulcerative Colitis | week 24 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
| Secondary | impact of Ulcerative Colitis | week 52 | To assess the impact of Ulcerative Colitis and therapy with TOFA on Work Productivity and Activity Impairment through the administration of WPAI Questionnaire at baseline |
| Secondary | health-related quality of life | week 24 and 52 | To assess the health-related quality of life of the patients with the administration of the Short IBDQ at baseline |
| Secondary | health-related quality of life | week 52 | To assess the health-related quality of life of the patients with the administration of the Short IBDQ at baseline |
| Secondary | adverse events | 24 month | To report the rate of adverse events with TOFA |
| Secondary | redictors of joint response JR, steroid free joint response SFJR, clinical intestinal response CIR, and steroid free clinical intestinal remission SFCIR | 24 month | To assess the predictors of joint response JR, steroid free joint response SFJR, clinical intestinal response CIR, and steroid free clinical intestinal remission SFCIR |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05431283/registered